Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dilek Erdem

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Clinical Genitourinary Cancer|October 26, 2024
Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder CancerDeniz Tural, Cagatay Arslan, Fatih Selcukbiricik, et al.
The Journal of International Medical Research|April 7, 2016
The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumoursBahiddin Yilmaz, Dilek Erdem, Fatih Teker, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|December 27, 2014
The relationship of T helper-2 pathway components interleukin-4, interleukin-10, immunoglobulin e, and eosinophils with prognostic markers in non-hodgkin lymphoma: a case-control studyNil Güler, Engin Kelkitli, Hilmi Atay, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 19, 2012
Red cell distribution width and mean platelet volume in amyloidosisEmre Erdem, Dilek Erdem, Melda Dilek, et al.
Ulusal Cerrahi Dergisi|October 28, 2015
Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical detailsKoray Topgül, Mehmet Bilge Çetinkaya, N Çiğdem Arslan, et al.
Clinical Genitourinary Cancer|January 14, 2023
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical PracticeDeniz Tural, Cagatay Arslan, Fatih Selcukbiricik, et al.
The Tohoku Journal of Experimental Medicine|October 7, 2015
Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast CancerTurkan Ozturk Topcu, Halil Kavgaci, Feyyaz Ozdemir, et al.
Journal of Cancer Research and Therapeutics|May 6, 2023
Discoidin domain receptor 1 as a promising biomarker for high-grade gliomasDilek Erdem, Meral Gunaldi, Irem Karaman, et al.
International Journal of Clinical and Experimental Medicine|July 2, 2015
Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter studyMeral Gunaldi, Sema Goksu, Dilek Erdem, et al.
Medicina (Kaunas, Lithuania)|January 8, 2025
Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with ImmunotherapyEzgi Değerli, Çağatay Arslan, Fatih Selçukbiricik, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Clinical Genitourinary Cancer|October 26, 2024
Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder CancerDeniz Tural, Cagatay Arslan, Fatih Selcukbiricik, et al.
The Journal of International Medical Research|April 7, 2016
The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumoursBahiddin Yilmaz, Dilek Erdem, Fatih Teker, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|December 27, 2014
The relationship of T helper-2 pathway components interleukin-4, interleukin-10, immunoglobulin e, and eosinophils with prognostic markers in non-hodgkin lymphoma: a case-control studyNil Güler, Engin Kelkitli, Hilmi Atay, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 19, 2012
Red cell distribution width and mean platelet volume in amyloidosisEmre Erdem, Dilek Erdem, Melda Dilek, et al.
Ulusal Cerrahi Dergisi|October 28, 2015
Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical detailsKoray Topgül, Mehmet Bilge Çetinkaya, N Çiğdem Arslan, et al.
Clinical Genitourinary Cancer|January 14, 2023
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical PracticeDeniz Tural, Cagatay Arslan, Fatih Selcukbiricik, et al.
The Tohoku Journal of Experimental Medicine|October 7, 2015
Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast CancerTurkan Ozturk Topcu, Halil Kavgaci, Feyyaz Ozdemir, et al.
Journal of Cancer Research and Therapeutics|May 6, 2023
Discoidin domain receptor 1 as a promising biomarker for high-grade gliomasDilek Erdem, Meral Gunaldi, Irem Karaman, et al.
International Journal of Clinical and Experimental Medicine|July 2, 2015
Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter studyMeral Gunaldi, Sema Goksu, Dilek Erdem, et al.
Medicina (Kaunas, Lithuania)|January 8, 2025
Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with ImmunotherapyEzgi Değerli, Çağatay Arslan, Fatih Selçukbiricik, et al.
Pageof 6